MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research cut shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) from a buy rating to a hold rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany. “

Separately, Guggenheim assumed coverage on shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 in a research note on Wednesday, November 27th. They set a buy rating on the stock.

MOR opened at $30.76 on Tuesday. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a fifty-two week low of $22.46 and a fifty-two week high of $37.96. The company’s 50-day moving average price is $33.52 and its 200 day moving average price is $30.59.

Recommended Story: What is the Gross Domestic Product (GDP)?

Get a free copy of the Zacks research report on MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 and related companies with MarketBeat.com's FREE daily email newsletter.